Skip to main content

Aortic Stenosis clinical trials at UC Health
6 in progress, 3 open to eligible people

  • Aortic Valve Replacement Without Major Surgery for Patients With Aortic Stenosis (Narrowing of the Aortic Heart Valve)

    “You are being considered for this research study because you have severe aortic stenosis (narrowing of the aortic valve) without symptoms.”

    open to eligible people ages 65 years and up

    This clinical trial is a prospective, randomized, controlled, multi-center study. Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 THV or clinical surveillance. Patients will be stratified by whether or not they are able to perform a treadmill stress test. Patients who have a positive stress test will be followed in a registry to collect data on subsequent treatment and mortality, as applicable.

    at UC Davis

  • Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome

    open to eligible females ages 16 years and up

    For fetuses with severe aortic stenosis, in utero balloon aortic valvuloplasty may improve fetal growth of left heart structures and thus improve potential for biventricular repair strategies after birth.

    at UCSF

  • The PARTNER 3 - AVIV Trial

    open to eligible people ages 19 years and up

    To assess the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients with a failing aortic bioprosthetic valve.

    at UCLA

  • Mitroflow DL Post Approval Study- North America

    Sorry, in progress, not accepting new patients

    Prospective, non-randomized, multicenter post-approval study to collect long term clinical and echographic data on Mitroflow DL patients.

    at UCLA

  • Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement

    Sorry, not currently recruiting here

    The objective of this study is to evaluate the safety and effectiveness of the Lotus™ Valve System and LOTUS Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe native aortic stenosis who are considered at extreme or high risk for surgical valve replacement.

    at UC Davis

  • The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

    Sorry, not currently recruiting here

    To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients with severe, calcific aortic stenosis who are at low operative risk for standard aortic valve replacement (AVR).

    at UCLA

Last updated: